Table 2. Comparison of previously reported cases of rhabdomyolysis associated with concomitant ticagrelor and rosuvastatin therapy and the present case. The table summarizes patient characteristics, rosuvastatin dose, time to onset, peak CK levels, AKI, requirement for renal replacement therapy, and clinical outcomes.

AKI: acute kidney injury, CK: creatine kinase, MI: myocardial infarction, NR: not reported, NSTEMI: non-ST-elevation myocardial infarction, PCI: percutaneous coronary intervention, ST: ST segment

Study	Patient characteristics	Rosuvastatin dose	Time to rhabdomyolysis	Peak CK	AKI	Renal replacement therapy	Outcome
Kostapanos et al., 2008 [7]	Patient with acute coronary syndrome/PCI receiving ticagrelor and rosuvastatin	Not clearly reported	After initiation of ticagrelor	NR	Yes	Not reported	Renal function deteriorated; rhabdomyolysis attributed to increased rosuvastatin exposure
Samuel et al., 2017 [12]	Post-MI patient receiving high-intensity rosuvastatin and ticagrelor	High-intensity dose	~1 month	338,601 IU/L	Yes	Hemodialysis (4 sessions)	Clinical and renal improvement after withdrawal of both drugs
Sibley et al., 2021 [6]	74-year-old man after non-ST-elevation myocardial infarction and drug-eluting stent implantation	40 mg/day	~1 month	NR	Yes	Not clearly reported	Improved after discontinuation
Lehtisalo et al., 2023 - patient A [8]	Older man after ST-elevation myocardial infarction/PCI	20-40 mg/day	~1-2 months	NR	Yes	Dialysis	Renal function recovered after discontinuation
Lehtisalo et al., 2023 - patient B [8]	Woman in her 80s after unstable angina	20-40 mg/day	~1 month	NR	No significant AKI	No	Recovered after rosuvastatin discontinuation
Lehtisalo et al., 2023 - patient C [8]	Woman in her 60-70s after NSTEMI/PCI	20-40 mg/day	~6 months	NR	Severe AKI	No	Renal function recovered after discontinuation
Present case	Patient receiving rosuvastatin and ticagrelor after coronary intervention	40 mg/day	~1 month	53,427 U/L	Yes	Yes	CK normalized to 89 U/L by day 20; renal function subsequently improved